Evaluation of Xa inhibitors as potential inhibitors of the SARS-CoV-2 Mpro protease
K Papaj, P Spychalska, P Kapica, A Fischer, J Nowak… - PLoS …, 2022 - journals.plos.org
Based on previous large-scale in silico screening several factor Xa inhibitors were proposed
to potentially inhibit SARS-CoV-2 Mpro. In addition to their known anticoagulants activity this …
to potentially inhibit SARS-CoV-2 Mpro. In addition to their known anticoagulants activity this …
HIGH HEPARANASE LEVEL IN SURVIVORS OF COVID-19—INDICATOR OF VASCULAR AND PULMONARY RECOVERY?
H Neb, SR Talbot, K Ruskowski, D Brkic… - Shock, 2022 - journals.lww.com
Background: Severe progression of coronavirus disease 2019 (COVID-19) causes
respiratory failure and critical illness. Recently, COVID-19 has been associated with …
respiratory failure and critical illness. Recently, COVID-19 has been associated with …
[HTML][HTML] Thromboprophylaxis in COVID‐19: weight and severity adjusted intensified dosing
MM Engelen, C Vandenbriele, V Spalart… - Research and Practice …, 2022 - Elsevier
Background Venous thromboembolism (VTE) frequently occurs in hospitalized patients with
coronavirus disease 2019 (COVID‐19). The optimal dose of anticoagulation for …
coronavirus disease 2019 (COVID‐19). The optimal dose of anticoagulation for …
Uma análise acerca das características das coagulopatias na Covid-19: revisão de literatura
DB Carvalho, VL Ferreira, CM Assunção… - Revista Eletrônica …, 2022 - acervomais.com.br
Objetivo: Analisar as características das coagulopatias associadas à infecção pelo novo
coronavírus. Revisão bibliográfica: Com o avanço da doença percebeu-se que além de …
coronavírus. Revisão bibliográfica: Com o avanço da doença percebeu-se que além de …
Conventional and synchronous spectrofluorometric determination of the recently administered drugs for treatment of COVID-19 favipiravir and apixaban
COVID-19 is a fast-spreading pandemic that is caused by SARS-CoV-2 viral pathogen.
Combination therapy of the antiviral favipiravir and the anticoagulant apixaban is one of the …
Combination therapy of the antiviral favipiravir and the anticoagulant apixaban is one of the …
Chronic Oral Anticoagulation Therapy and Prognosis of Patients Admitted to Hospital for COVID‐19: Insights from the HOPE COVID‐19 Registry
JM Rivera-Caravaca, IJ Núñez-Gil… - … journal of clinical …, 2022 - Wiley Online Library
Background. Most evidence regarding anticoagulation and COVID‐19 refers to the
hospitalization setting, but the role of oral anticoagulation (OAC) before hospital admission …
hospitalization setting, but the role of oral anticoagulation (OAC) before hospital admission …
Clinical and laboratory factors associated with mortality among hospitalized patients with COVID-19 infection in Lebanon: A multicenter study
M Chebli, A Shebly, G Kerbage, CJ El Zouki, E Hayek… - Plos one, 2022 - journals.plos.org
Background With the dire economic situation in Lebanon, many of the basic resources of the
hospitals needed to help fight COVID-19 infections are not available. In this paper, we …
hospitals needed to help fight COVID-19 infections are not available. In this paper, we …
Safety and efficacy analysis of apixaban compared to heparins in hospitalized non-critically ill COVID-19 patients
D Appiah, NJ Quinn, EG Messing… - Hospital …, 2022 - journals.sagepub.com
Purpose: Heparin-based regimens are recommended for anticoagulation in hospitalized
patients with COVID-19 though a study reported similar mortality with apixaban in critically ill …
patients with COVID-19 though a study reported similar mortality with apixaban in critically ill …
COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study
ОL Kochneva, M Kislova, EI Zhelnova… - Leukemia & …, 2022 - Taylor & Francis
We describe a retrospective cohort, 156 patients with chronic lymphocytic leukemia (CLL)
diagnosed with COVID-19, analyze factors associated with a severe disease course and the …
diagnosed with COVID-19, analyze factors associated with a severe disease course and the …
Increased incidence of thrombosis in a cohort of cancer patients with COVID-19
Background: Increased rates of thromboembolism (TE) have been reported in patients with
COVID-19, even without prior predisposition to thrombosis. Cancer patients are already …
COVID-19, even without prior predisposition to thrombosis. Cancer patients are already …